Vir Biotechnology Inc
$ 8.82
0.63%
07 Aug - close price
- Market Cap 1,492,485,000 USD
- Current Price $ 8.82
- High / Low $ 9.03 / 8.75
- Stock P/E N/A
- Book Value 5.04
- EPS -1.78
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.26 %
- 52 Week High 11.66
- 52 Week Low 4.16
About
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
Analyst Target Price
$21.11
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-23 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-10-31 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 |
| Reported EPS | 0.47 | -0.85 | -0.31 | -1.17 | -0.8 | -0.88 | -0.76 | -1.56 | -1.02 | -0.48 | -0.86 | -1.22 |
| Estimated EPS | 0.83 | 0.48 | -0.54 | -0.7 | -0.72 | -0.84 | -0.89 | -1.08 | -0.89 | -1.05 | -1.01 | -1.19 |
| Surprise | -0.36 | -1.33 | 0.23 | -0.47 | -0.08 | -0.04 | 0.13 | -0.48 | -0.13 | 0.57 | 0.15 | -0.03 |
| Surprise Percentage | -43.3735% | -277.0833% | 42.5926% | -67.1429% | -11.1111% | -4.7619% | 14.6067% | -44.4444% | -14.6067% | 54.2857% | 14.8515% | -2.521% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VIR
2026-08-08 08:10:12
Vir Biotechnology (VIR) reported a significant swing to profitability in Q2 2026, with US$80.08 million in net income and sharply increased revenue of US$238.95 million. Despite this improvement, the company missed analyst expectations for both earnings and sales. The article discusses how this mixed performance, alongside strategic collaborations like the Astellas partnership, shapes Vir Biotechnology's investment outlook, emphasizing clinical execution and commercialization as key catalysts.
2026-08-08 05:10:12
Wall Street Zen has upgraded Vir Biotechnology (NASDAQ:VIR) from a "sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with a $20.62 target price. The company recently reported strong quarterly earnings, beating EPS and revenue estimates significantly, with revenue soaring by 19582.5% year-over-year. Institutional investors hold a substantial portion of the company, while insider activity showed a director selling a portion of her shares.
2026-08-06 10:41:44
Vir Biotechnology reported its second-quarter 2026 financial results, highlighting strong progress in its clinical programs for chronic hepatitis delta (CHD) and solid tumors. Key updates include promising Phase 2 SOLSTICE data for elebsiran and tobevibart in CHD, with Phase 3 ECLIPSE 1 trial data expected in Q4 2026, and the initiation of dose-expansion cohorts for VIR-5500 in prostate cancer following a collaboration with Astellas. The company ended the quarter with over $1 billion in cash, cash equivalents, and investments, with a net income of $80.1 million.
2026-08-06 07:40:12
The average 12-month price target for Vir Biotechnology, Inc. (VIR) stock has been lowered by analysts from $21.56 to $21.11, with individual forecasts ranging from $16 to $30 per share. This updated target suggests a potential upside of approximately 132% based on the August 5th closing price. Despite the target cut, the consensus rating from 10 analysts remains a "Buy," with no "Hold" or "Sell" recommendations.
2026-08-06 00:46:43
Vir Biotechnology, Inc. (VIR) reported Q2 earnings of $0.47 per share, significantly missing the Zacks Consensus Estimate of $0.83, though it represents an improvement from a loss of $0.8 per share a year ago. The company also missed revenue estimates, posting $238.95 million against an expectation of $258.38 million. Despite these misses, VIR shares have seen a 52.1% gain year-to-date, outperforming the S&P 500.
2026-08-05 23:46:44
Vir Biotechnology reported strong Q2 2026 results, with net income of $80.1 million and cash reserves exceeding $1 billion, largely due to a collaboration payment from Astellas. The company's stock jumped over 10% after hours as investors reacted positively to the improved financial standing, promising hepatitis delta clinical data, and clear upcoming clinical milestones. Vir is advancing its hepatitis delta program with Phase III data expected later this year and early next, alongside progress in its oncology pipeline through the PRO-XTEN platform.
